INSERM U1088, CURS, Amiens, France; Division of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt/Paris, France; INSERM U1018, Team 5, CESP, UVSQ, Villejuif, France.
INSERM U1088, CURS, Amiens, France; Division of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt/Paris, France; INSERM U1018, Team 5, CESP, UVSQ, Villejuif, France.
Adv Chronic Kidney Dis. 2018 May;25(3):281-290. doi: 10.1053/j.ackd.2017.12.001.
Vascular calcification (VC) is associated with elevated cardiovascular mortality rates in patients with CKD. Recent clinical studies of patients with advanced CKD have observed an association between low serum magnesium (Mg) levels on one hand and elevated VC and cardiovascular mortality on the other. These findings have stimulated interest in understanding Mg's impact on CKD in general and the associated VC in particular. In vitro and preclinical in vivo data indicate that Mg has the potential to protect vascular smooth muscle cells against calcification via several different molecular mechanisms. Accordingly, data from pilot interventional studies in the clinic suggest that oral Mg supplementation reduces VC in patients with CKD. The present review provides an overview of our current understanding of the impact of Mg on the development of VC in patients with CKD.
血管钙化（VC）与 CKD 患者心血管死亡率升高有关。最近对晚期 CKD 患者的临床研究观察到，一方面血清镁（Mg）水平低，另一方面 VC 升高和心血管死亡率升高。这些发现激发了人们对理解 Mg 对 CKD 一般和相关 VC 特别是影响的兴趣。体外和临床前体内数据表明，Mg 具有通过几种不同的分子机制保护血管平滑肌细胞免受钙化的潜力。因此，来自临床初步干预研究的数据表明，口服 Mg 补充剂可减少 CKD 患者的 VC。本综述提供了我们目前对 Mg 对 CKD 患者 VC 发展影响的理解概述。
